Your browser doesn't support javascript.
loading
Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes.
Riad, A; Westermann, D; Van Linthout, S; Mohr, Z; Uyulmaz, S; Becher, P M; Rütten, H; Wohlfart, P; Peters, H; Schultheiss, H-P; Tschöpe, C.
Afiliación
  • Riad A; Department of Cardiology and Pneumology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12206, Berlin, Germany.
Diabetologia ; 51(12): 2325-32, 2008 Dec.
Article en En | MEDLINE | ID: mdl-18825362
ABSTRACT
AIMS/

HYPOTHESIS:

Reduced bioavailability of nitric oxide (NO) is a hallmark of diabetes mellitus-induced vascular complications. In the present study we investigated whether a pharmacological increase of endothelial NO synthase (eNOS) production can restore the impaired hindlimb flow in a rat model of severe diabetes.

METHODS:

A model of diabetes mellitus was induced in male Sprague-Dawley rats by a single injection of streptozotozin. Rats were treated chronically with the eNOS transcription enhancer AVE3085 (10 mg [kg body weight](-1) day(-1); p.o.) or vehicle for 48 days and compared with controls. Endothelial function and arterial BP were investigated in vivo using an autoperfused hindlimb model and TIP-catheter measurement, respectively. Protein production of eNOS, total and phosphorylated vasodilator-stimulated phosphoprotein (VASP) were assessed in their quadriceps muscle tissue, whereas cyclic GMP (cGMP) concentrations were assessed in blood plasma. RNA levels of intracellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1) were measured by real-time PCR.

RESULTS:

Untreated diabetic rats showed significantly reduced quadriceps muscle contents of eNOS (-64%) and phosphorylated VASP (-26%) protein associated with impaired vascular function (maximum vasodilatation -30%, p < 0.05) and enhanced production of ICAM-1 (+121%) and VCAM-1 (+156%). Chronic treatment with AVE3085 did not alter arterial BP or severe hyperglycaemia, but did lead to significantly increased production of eNOS (+95%), cGMP (+128%) and VASP phosphorylation (+65%) as well as to improved vascular function (+36%) associated with reduced production of ICAM-1 (-36%) and VCAM-1 (-58%). CONCLUSIONS/

INTERPRETATION:

In a rat model of severe diabetes, pharmacological enhancement of impaired eNOS production and NO-cGMP signalling by AVE3085 restores altered hindlimb blood flow and prevents vascular inflammation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Complicaciones de la Diabetes / Diabetes Mellitus Experimental / Óxido Nítrico Sintasa de Tipo III / Miembro Posterior Límite: Animals / Humans / Male Idioma: En Revista: Diabetologia Año: 2008 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Complicaciones de la Diabetes / Diabetes Mellitus Experimental / Óxido Nítrico Sintasa de Tipo III / Miembro Posterior Límite: Animals / Humans / Male Idioma: En Revista: Diabetologia Año: 2008 Tipo del documento: Article País de afiliación: Alemania